Thiosemicarbazones functioning as zinc metallochaperones to reactivate mutant p53

X Yu, A Blanden, AT Tsang, S Zaman, Y Liu… - Molecular …, 2017 - ASPET
Small-molecule restoration of wild-type structure and function to mutant p53 (so-called
mutant reactivation) is a highly sought-after goal in cancer drug development. We previously …

Outcomes of microwave ablation for colorectal cancer liver metastases: a single center experience

OS Eng, AT Tsang, D Moore, C Chen… - Journal of surgical …, 2015 - Wiley Online Library
Background and Objectives Surgical management of colorectal cancer liver metastases
continues to evolve to optimize oncologic outcomes while maximizing parenchymal preservation…

Zinc metallochaperones reactivate mutant p53 using an ON/OFF switch mechanism: a new paradigm in cancer therapeutics

X Yu, S Kogan, Y Chen, AT Tsang, T Withers, H Lin… - Clinical cancer …, 2018 - AACR
Purpose: Zinc metallochaperones (ZMC) are a new class of anticancer drugs that reactivate
zinc-deficient mutant p53 by raising and buffering intracellular zinc levels sufficiently to …

U1 Adaptors Suppress the KRAS-MYC Oncogenic Axis in Human Pancreatic Cancer Xenografts

AT Tsang, C Dudgeon, L Yi, X Yu, R Goraczniak… - Molecular cancer …, 2017 - AACR
Targeting KRAS and MYC has been a tremendous challenge in cancer drug development.
Genetic studies in mouse models have validated the efficacy of silencing expression of both …

[HTML][HTML] Maintaining Contour with a Three-dimensional Interstitial Tissue Marker in 134 Lumpectomies

AT Tsang, L Cai, J Edquilang… - Plastic and Reconstructive …, 2021 - journals.lww.com
Background: Breast-conserving surgery (BCS) is meant to preserve the natural appearance
of the breast; however, tissue volume deficits cannot always be compensated by soft tissue …

Acute Pancreatitis After Pancreaticoduodenectomy

AT Tsang, S Belsley - JAMA surgery, 2017 - jamanetwork.com
Discussion The computed tomographic scan demonstrated a distended stomach, with
intussusception of the afferent limb of the gastrojejunostomy from the patient’s Whipple procedure …

[HTML][HTML] 694. Targeting KRAS in Pancreatic Cancer by Gene Silencing with U1 Adaptors

AT Tsang, X Yu, R Goraczniak, M Brenneman… - Molecular Therapy, 2015 - cell.com
Conventional si/shRNA designs are restricted to Watson/Crick pairing between guide strand
and target RNA as this has been deemed crucial for potent Argonaute 2 based slicer activity…

Abstract B52: Therapeutic targeting of human KRAS in pancreatic cancer using a novel method of gene-silencing: U1 adaptors

AT Tsang, X Yu, R Goraczniak, M Brenneman… - Molecular Cancer …, 2014 - AACR
Background: While genetic knockdown of RAS in mouse tumor models has substantiated it
as a therapeutic target, there is no effective means of targeting RAS currently available in the …

Abstract B211: Cellular zinc homeostatic mechanisms function as an off switch for zinc metallochaperone-mediated reactivation of mutant p53

X Yu, S Kogan, Y Chen, AT Tsang, T Withers… - Molecular Cancer …, 2018 - AACR
The p53 transcription factor functions as one of cancer’s most potent tumor suppressors and
is the most frequently mutated gene in human cancer. The majority of p53 mutations (>70%) …

Pre-clinical studies of a mutant p53 reactivating drug in pancreatic cancer

X Yu, AT Tsang, Z Li, OS Eng, H Lin, M Gounder… - Cancer Research, 2015 - AACR
Pancreatic cancer therapy suffers from a lack of effective chemotherapy. TP53 is second
only to Kras as the most commonly mutated gene in pancreatic cancer with point mutations …